Drug Profile
Hydromorphone extended release - Ensysce Biosciences
Alternative Names: ER hydromorphone - Ensysce; PF-0329; PF-329Latest Information Update: 11 Oct 2023
Price :
$50
*
At a glance
- Originator PharmacoFore
- Developer Ensysce Biosciences
- Class Morphine derivatives; Opioid analgesics; Small molecules
- Mechanism of Action Opioid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Pain
Most Recent Events
- 11 Oct 2023 Hydromorphone extended release is still in phase I trials for Pain in Australia (PO, Controlled release) (Ensysce Biosciences pipeline, October 2023)
- 28 Jul 2018 No recent reports of development identified for phase-I development in Pain in Australia (PO, Controlled release)
- 22 Mar 2016 Phase I development is ongoing in Australia